Stay updated on Efprezimod Alfa as Immunomodulator in COVID-19 Clinical Trial

Sign up to get notified when there's something new on the Efprezimod Alfa as Immunomodulator in COVID-19 Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Efprezimod Alfa as Immunomodulator in COVID-19 Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    Added a Locations section listing study sites in Florida, Maryland, New Jersey, Ohio, and Texas with revision v3.3.3. Removed the separate state-location entries for Florida, Maryland, New Jersey, Ohio, and Texas and the HHS Vulnerability Disclosure link.
    Difference
    0.6%
    Check dated 2025-12-23T22:50:26.000Z thumbnail image
  2. Check
    9 days ago
    No Change Detected
  3. Check
    16 days ago
    No Change Detected
  4. Check
    30 days ago
    Change Detected
    Summary
    Publications section now indicates entries are automatically filled from PubMed and may not all pertain to the study, and the revision version was updated to v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2025-11-25T13:35:32.000Z thumbnail image
  5. Check
    38 days ago
    Change Detected
    Summary
    Deleted the notice about funding lapse that informed users about potential delays and where to check operating status. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.3%
    Check dated 2025-11-18T07:19:29.000Z thumbnail image
  6. Check
    52 days ago
    Change Detected
    Summary
    The new screenshot shows minor formatting and layout changes with no substantive updates to the study details, outcomes, or eligibility criteria. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2025-11-03T21:25:25.000Z thumbnail image
  7. Check
    81 days ago
    Change Detected
    Summary
    Updated version to v3.2.0 and added a government operating-status notice for NIH Clinical Center, directing users to cc.nih.gov and opm.gov.
    Difference
    3%
    Check dated 2025-10-06T05:56:45.000Z thumbnail image
  8. Check
    88 days ago
    Change Detected
    Summary
    Replaces/phases out pharmaceutical-solution categories with broader chemical categories and updates the version to v3.1.0; several prior solution-related terms are removed.
    Difference
    0.9%
    Check dated 2025-09-29T03:12:51.000Z thumbnail image

Stay in the know with updates to Efprezimod Alfa as Immunomodulator in COVID-19 Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Efprezimod Alfa as Immunomodulator in COVID-19 Clinical Trial page.